Back to search results

APR-TD011 Spray for Cutaneous T Cell Lymphoma Skin Lesions

This study is looking at how a wound cleansing spray called APR-TD011 (also known as RLF-TD011) affects the bacteria and other tiny organisms (microbiome) on skin lesions in people with early-stage cutaneous T cell lymphoma (CTCL). Researchers also want to see how well people tolerate the spray. You might be able to join if you are an adult with early-stage mycosis fungoides (a type of CTCL) and have specific skin lesions that are at least 10 square centimeters and test positive for Staphylococcus aureus bacteria. The main goal is to see how the microbiome changes after 4 weeks of using the spray. The study plans to enroll 30 participants, but its current status is unclear.

Study design
This is an open-label pilot study, meaning both you and the researchers will know what treatment you are receiving. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 4 weeks, suggesting follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05728879

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Northwestern University
~30 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:APR-TD011 (RLF-TD011)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in microbiome species
Measured over 4 weeks

Conditions

Cutaneous T Cell Lymphoma

Explore related trials

Mycosis Fungoides

NCT05728879

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dermatology CTU

    Chicago, Illinoisstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Dermatology CTU
[email protected]
312-503-5944
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults with early-stage mycosis fungoides (stages IA-IB)
At least two target lesions that have been present for at least 3 weeks and is at least 10 cm2 , so that at least one lesion may be allocated to each of the treatment regimes
Target lesion with swab that is culture positive for staphylococcus aureus, but not to an extent that would require systemic antibiotics
Agree to avoid washing or using a topical application at the target lesion starting the night before each scheduled study visit.
Agree for the duration of study participation to avoid using dilute bleach or vinegar baths, or other antiseptic use, at the target lesion from screening throughout the study.

Exclusion

Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics adults unable to provide informed consent, (infants, children, teenagers, pregnant women, prisoners and other vulnerable populations.

What this trial measures

  • Change in microbiome species4 weeks

    Reduction of Staphylococcus aureus relative abundance between baseline and Week 4